FDA greenlights Rivanna’s AI musculoskeletal imaging system

With FDA clearance in hand, Rivanna highlighted that it will accelerate the development of further AI capabilities for the Accuro XV system. With FDA clearance in hand, Rivanna highlighted that it will accelerate the development of further AI capabilities for the Accuro XV system. A recent feasibility study of Accuro XV found that more than 90% of scans in both operator groups were rated adequate for diagnostic interpretation. Credit: Piotr Swat / Shutterstock.com Rivanna’s Accuro XV has secured US Food and Drug Administration (FDA) clearance, setting the stage for the artificial intelligence (AI)-based musculoskeletal imaging system’s commercialisation across hospitals and…

Source: Medical Device Network